Abivax SA (ABVX) vs Twist Bioscience (TWST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Twist Bioscience (TWST) has outperformed Abivax SA (ABVX) over the past year, gaining 363.7% versus a gain of 2.9%. Twist Bioscience is the larger company by market cap ($10.08 billion vs $7.77 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABVX | TWST |
|---|---|---|
| Share price | $89.05 | $152.05 |
| Market cap | $7.77B | $10.08B |
| 1-day change | +2.34% | -2.31% |
| YTD return | -33.97% | +379.35% |
| 1-year return | +2.94% | +363.71% |
| 5-year return | — | +34.80% |
| EPS (TTM) | $-6.08 | $-2.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $376.57M |
| Revenue growth (YoY) | — | +20.32% |
| Net income (latest FY) | — | $-77.67M |
| Gross margin | — | 50.72% |
| Operating margin | — | -36.18% |
| Net margin | — | -20.63% |
| 52-week high | $148.83 | $219.71 |
| 52-week low | $69.81 | $23.30 |
| Distance from 52-week high | -40.17% | -30.80% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +84.17% | -1.13% |
| Average volume | 1.11M | 2.04M |
| Shares outstanding | 87.27M | 66.30M |
| Employees | 98 | 979 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TWST has outperformed ABVX by 360.8 percentage points over the past year.
About Abivax SA
ABVX stock →ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 98 employees
About Twist Bioscience
TWST stock →Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 979 employees
ABVX vs TWST FAQ
Which is bigger, Abivax SA or Twist Bioscience?
Twist Bioscience (TWST) is larger, with a market capitalization of $10.08B compared with $7.77B for Abivax SA (ABVX).
Which stock has performed better over the past year, ABVX or TWST?
TWST returned +363.71% over the past 12 months, compared with +2.94% for ABVX (price return, excluding dividends). Past performance does not predict future results.
Are Abivax SA and Twist Bioscience in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Abivax SA and Biotechnology: Biological Products (No Diagnostic Substances) for Twist Bioscience.